

I. ESTIMATED RESULTS FOR THE PERIOD

(I) Period of estimated results

From 1 January 2022 to 30 September 2022.

(II) Estimated results

The preliminary estimates made by the Company's finance department are as follows:

1. It is expected that the net profit attributable to the shareholders of the Company for the period from January to September 2022 will increase from approximately RMB359.2264 million to RMB408.8276 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 144.8% to 164.8%.
2. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the period from January to September 2022 will increase by approximately RMB366.4033 million to RMB409.8683 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 168.6% to 188.6%. The net profits attributable to shareholders of the Company after deducting non-recurring profit and loss will record a period-on-period increase of approximately 61.0% to 81.0% as compared with the data in the financial statements for the corresponding period of last year, after excluding the unrealized gain from the fair value change of biological assets, interest income and the effects of exchange gains and losses.

(III) The estimated results have not been audited by certified public accountants.

II. RESULTS FOR THE CORRESPONDING PERIOD OF LAST YEAR

Net profit attributable to shareholders of the Company for the corresponding period of last year: RMB248.0062 million. Net profit attributable to shareholders of the Company after deducting non-recurring profit or loss: RMB217.3254 million; earnings per share: RMB0.95.

III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS DURING THE PERIOD

- (I) The financial results increment was mainly attributable to the following factors: (i) the Company has strengthened technological innovation and continues to strengthen its research and development support for innovative drugs, gaining the trust of innovative research and development enterprise; (ii) the Company has further improved its capacity and scheduled its projects properly, in order

to further improve its capacity utilization rate, ensuring smooth delivery of the orders on hand; the scale of scientific research and technical team has expanded with the addition of more mature technical personnel, providing strong guarantee for performance growth; (iii) the Company has further allocated its resources and continued to facilitate and strengthen its work in the supply sessions of the upstream industry chain, so as to guarantee and enhance the continuous service capability of the Company; (iv) the Company's capital management causes positive impact on overall performance.

- (II) Impact of non-operating profit or loss. It was mainly due to various factors such as government subsidies, gains on financial assets held for trading and acquisition of negative goodwill. The impact of non-recurring gains and losses on net profit after income tax was approximately RMB26.60 million, which is basically the same for the corresponding period of last year.

IV. RISK WARNING

There are no material uncertainties affecting the accuracy of the estimated results.

V. OTHER EXPLANATION

The financial data contained in this results estimate is prepared in accordance with the China Accounting Standards for Business Enterprises and the estimated data is only preliminary accounting figures. The specific and accurate financial data shall refer to the unaudited 2022 third quarterly results announcement and the 2022 Third Quarterly Report prepared in accordance with the China Accounting Standards for Business Enterprises or the International Financial Reporting Standards officially disclosed by the Company. Investors are advised to pay attention to investment risks.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chair, Executive

Hong Kong, October 18, 2022

All the data of this announcement, the Board of the Company, Mr. Feng Yuxia, the Chair, Executive and Executive Director, Mr. Zou Conglin, Mr. Gao Daqiang, Mr. Sun Yuxia and Dr. Ya Dalin, Executive Director, Mr. Gu Xiaolei, a non-executive Director, and Mr. Sun Mingcheng, Dr. Zhai Yungang, Mr. O Xiajie and Mr. Zhang Fan, independent non-executive Director.